| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Shenzhen Neptunus Bioengineering Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.27 |
| 52 Week High | CN¥3.51 |
| 52 Week Low | CN¥2.01 |
| Beta | 0.41 |
| 1 Month Change | 4.61% |
| 3 Month Change | -10.98% |
| 1 Year Change | -31.63% |
| 3 Year Change | -34.39% |
| 5 Year Change | -42.09% |
| Change since IPO | -66.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 78 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | -4.6% | -1.1% | 1.3% |
| 1Y | -31.6% | -30.5% | -9.1% |
Return vs Industry: 000078 underperformed the CN Healthcare industry which returned -30.5% over the past year.
Return vs Market: 000078 underperformed the CN Market which returned -9.1% over the past year.
Price Volatility
| 78 volatility | |
|---|---|
| 78 Average Weekly Movement | 5.0% |
| Healthcare Industry Average Movement | 5.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in CN Market | 10.6% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 000078 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000078's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 9,093 | Feng Zhang | www.neptunusbio.com |
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and provides value-added services for hospitals, medical institutions, and drug retail institutions and distributors.
Shenzhen Neptunus Bioengineering Co., Ltd. Fundamentals Summary
| 78 fundamental statistics | |
|---|---|
| Market cap | CN¥6.24b |
| Earnings (TTM) | -CN¥1.72b |
| Revenue (TTM) | CN¥34.55b |
0.2x
P/S Ratio-3.6x
P/E RatioIs 78 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 78 income statement (TTM) | |
|---|---|
| Revenue | CN¥34.55b |
| Cost of Revenue | CN¥31.25b |
| Gross Profit | CN¥3.30b |
| Other Expenses | CN¥5.02b |
| Earnings | -CN¥1.72b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 9.54% |
| Net Profit Margin | -4.98% |
| Debt/Equity Ratio | 258.2% |
How did 78 perform over the long term?
See historical performance and comparison